{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:20:34Z","timestamp":1790274034730,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["419699"],"award-info":[{"award-number":["419699"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["704121"],"award-info":[{"award-number":["704121"]}],"id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.coph.2025.102537","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T11:17:56Z","timestamp":1746875876000},"page":"102537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Allogeneic double-negative T-cell therapy for acute myeloid leukemia"],"prefix":"10.1016","volume":"83","author":[{"given":"Enoch","family":"Tin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongbok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2025.102537_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102537_bib2","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102537_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00670-0","article-title":"Hypomethylating agent and venetoclax with FLT3 inhibitor \u201ctriplet\u201d therapy in older\/unfit patients with FLT3 mutated AML","volume":"12","author":"Yilmaz","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coph.2025.102537_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-024-01657-z","article-title":"Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1\/2 trial","volume":"18","author":"Cortes","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.coph.2025.102537_bib5","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1 -mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102537_bib6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.CCR-17-2228","article-title":"Allogeneic human double negative t cells as a novel immunotherapy for acute myeloid leukemia and its underlying mechanisms","volume":"24","author":"Lee","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102537_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0507-2","article-title":"Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15","volume":"7","author":"Yao","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coph.2025.102537_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.886645","article-title":"Double negative T regulatory cells : an emerging paradigm shift in reproductive immune tolerance?","volume":"13","author":"Bafor","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2025.102537_bib9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/cei.13145","article-title":"Infusion of ex-vivo expanded human TCR-\u03b1\u03b2+ double-negative regulatory T cells delays onset of xenogeneic graft-versus-host disease","volume":"193","author":"Achita","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coph.2025.102537_bib10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/biomedicines12010166","article-title":"Double-negative T (DNT) cells in patients with systemic lupus erythematosus","volume":"12","author":"Poddighe","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.coph.2025.102537_bib11","article-title":"CD3+CD4-CD8- (Double-Negative) T cells in inflammation, immune disorders and cancer","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2025.102537_bib12","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/leu.2011.99","article-title":"Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy","volume":"25","author":"Merims","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102537_bib13","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1158\/1078-0432.CCR-18-2291","article-title":"Developing allogeneic double-negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer","volume":"25","author":"Lee","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102537_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205039","article-title":"Enhancing therapeutic efficacy of double negative t cells against acute myeloid leukemia using idelalisib","volume":"13","author":"Kang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.coph.2025.102537_sref15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010684","article-title":"Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapy","volume":"13","author":"Tin","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coph.2025.102537_sref16","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1182\/bloodadvances.2023011739","article-title":"Double-negative T cells utilize a TNF\u03b1\u2013JAK1\u2013ICAM-1 cytotoxic axis against acute myeloid leukemia","volume":"8","author":"Tin","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102537_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pan.2018.12.006","article-title":"Antipancreatic cancer effect of DNT cells and the underlying mechanism","volume":"19","author":"Chen","year":"2019","journal-title":"Pancreatology"},{"key":"10.1016\/j.coph.2025.102537_sref18","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1126\/sciimmunol.abl3642","article-title":"Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities","volume":"7","author":"Vasic","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coph.2025.102537_sref19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007277","article-title":"Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells","volume":"11","author":"Fang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coph.2025.102537_bib20","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood.2019004108","article-title":"CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy","volume":"137","author":"Soares","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102537_bib21","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2025.102537_sref22","first-page":"OF1","article-title":"SOCS1 protects acute myeloid leukemia against allogeneic T cell\u2013mediated cytotoxicity","volume":"XX","author":"Tin","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.coph.2025.102537_bib23","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1136\/jitc-2023-006857","article-title":"Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia","volume":"11","author":"Wen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coph.2025.102537_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-05470-x","article-title":"Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1)","volume":"12","author":"Allende-Vega","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2025.102537_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fimmu.2015.00574","article-title":"A SOCS1\/3 antagonist peptide protects mice against lethal infection with influenza A virus","volume":"6","author":"Ahmed","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2025.102537_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-05728-w","article-title":"Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients","volume":"14","author":"Holicek","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.coph.2025.102537_bib27","first-page":"1","article-title":"SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis","volume":"12","author":"Song","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2025.102537_bib28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-22-2235","article-title":"Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced\/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib study","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102537_sref29","doi-asserted-by":"crossref","first-page":"E264","DOI":"10.1002\/ajh.26564","article-title":"Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: a first-in-human phase I study","volume":"97","author":"Tang","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.coph.2025.102537_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-018-0756-9","article-title":"Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy","volume":"37","author":"Chen","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102537_bib31","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2022-158518","article-title":"Long-term follow-up of the phase 3 Viale-a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy","volume":"140","author":"Pratz","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102537_bib32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T cell\u2013mediated antileukemic activity by increasing ROS production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102537_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.coph.2025.102537_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.coph.2025.102537_bib35","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41416-023-02221-1","article-title":"The emerging role of PI3K inhibitors for solid tumour treatment and beyond","volume":"128","author":"Belli","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.coph.2025.102537_sref36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13046-024-03247-w","article-title":"Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD","volume":"44","author":"Lee","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102537_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-023-01722-0","article-title":"Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment","volume":"22","author":"Gao","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.coph.2025.102537_bib38","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD Prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102537_bib39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.coph.2025.102537_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.coph.2025.102537_bib41","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102537_bib42","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-cells (CD33CART) for children and Young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102537_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-022-01703-0","article-title":"Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102537_bib44","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-Specific CAR T cells: a first-in-human clinical trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102537_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100751","article-title":"Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia","volume":"31","author":"Boucher","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.coph.2025.102537_bib46","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma","volume":"7","author":"Potnis","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102537_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access?","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.coph.2025.102537_sref48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102537_sref49","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","article-title":"Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia","volume":"29","author":"Anderson","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2025.102537_sref50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.coph.2025.102537_sref51","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102516","article-title":"CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study","volume":"70","author":"Xiao","year":"2024","journal-title":"eClinicalMedicine"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:26:34Z","timestamp":1774517194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489225000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":51,"alternative-id":["S1471489225000335"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2025.102537","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic double-negative T-cell therapy for acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2025.102537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102537"}}